Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07227805 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Evaluation of the Safety and Performance of the Novel Medtronic Experimental Automated Insulin Delivery System (NMX8) in People Living With Diabetes (NEXUS)

Study acronym: NEXUS
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Eligibility criteria expanded, about 27 words Secondary endpoints: details revised at 1 of 3 entries · Site details revised at 8 of 9 sites Show 2 more changesShow less
    • Secondary endpoints: details revised at 1 of 3 entries
    • Site details revised at 8 of 9 sites
  2. Recruitment opened Trial sites expanded: 0 → 9 locations · Start date changed from estimate of Jun 15, 2026 to Jul 19, 2026v2 Show 2 more changesShow less
    • Trial sites expanded: 0 → 9 locations
    • Start date changed from estimate of Jun 15, 2026 to Jul 19, 2026
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will demonstrate the safety and performance of the Novel Medtronic Experimental Automated Insulin Delivery system named MiniMed™ NMX8 system in people living with insulin-requiring diabetes in comparison with the MiniMed™ 780G system.
Trial Details
NCT Number NCT07227805
Lead Sponsor Medtronic MiniMed, Inc.
Conditions Diabetes (Insulin-requiring, Type 1 or Type 2)
Enrollment 116 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov